These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 19009280)
1. Detection of neutralizing antibodies with HCV pseudoparticles (HCVpp). Dreux M; Cosset FL Methods Mol Biol; 2009; 510():427-38. PubMed ID: 19009280 [TBL] [Abstract][Full Text] [Related]
2. [Development of infectious pseudo-particle harboring three subtypes hepatitis C virus glycoproteins and their application in neutralization assays]. Zhang K; Tan WJ; Deng Y; Li J; Wu XB; Ruan L Bing Du Xue Bao; 2008 Jul; 24(4):287-94. PubMed ID: 18780632 [TBL] [Abstract][Full Text] [Related]
3. Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp). Bailey JR; Urbanowicz RA; Ball JK; Law M; Foung SKH Methods Mol Biol; 2019; 1911():441-450. PubMed ID: 30593644 [TBL] [Abstract][Full Text] [Related]
4. Measurements of HCV neutralizing antibodies and of HCV-specific CD4+ and CD8+ cells using hepatitis C virus pseudo-particles (HCVpp). Berger A; Giroglou T; Leutz A; Ogbomo H; Pfaff K; Teuber G; Cinatl J; van Laer D; Doerr HW J Clin Virol; 2009 Sep; 46(1):55-60. PubMed ID: 19560398 [TBL] [Abstract][Full Text] [Related]
5. Studies on the role of neutralizing antibodies against envelope genes in resolving HCV pseudo-particles infection. Rafique S; Idrees M; Ali A; Iqbal M Mol Biol Rep; 2014 Jun; 41(6):3945-50. PubMed ID: 24566682 [TBL] [Abstract][Full Text] [Related]
7. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance. Urbanowicz RA; McClure CP; Brown RJ; Tsoleridis T; Persson MA; Krey T; Irving WL; Ball JK; Tarr AW J Virol; 2015 Dec; 90(7):3288-301. PubMed ID: 26699643 [TBL] [Abstract][Full Text] [Related]
8. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Lavillette D; Tarr AW; Voisset C; Donot P; Bartosch B; Bain C; Patel AH; Dubuisson J; Ball JK; Cosset FL Hepatology; 2005 Feb; 41(2):265-74. PubMed ID: 15660396 [TBL] [Abstract][Full Text] [Related]
9. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies. Vietheer PT; Boo I; Drummer HE; Netter HJ Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556 [TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles. Wasilewski LN; Ray SC; Bailey JR J Gen Virol; 2016 Nov; 97(11):2883-2893. PubMed ID: 27667373 [TBL] [Abstract][Full Text] [Related]
11. A model for the study of hepatitis C virus entry. Castet V; Moradpour D Hepatology; 2003 Sep; 38(3):771-4. PubMed ID: 12939604 [TBL] [Abstract][Full Text] [Related]
12. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Bartosch B; Bukh J; Meunier JC; Granier C; Engle RE; Blackwelder WC; Emerson SU; Cosset FL; Purcell RH Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14199-204. PubMed ID: 14617769 [TBL] [Abstract][Full Text] [Related]
13. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Meunier JC; Engle RE; Faulk K; Zhao M; Bartosch B; Alter H; Emerson SU; Cosset FL; Purcell RH; Bukh J Proc Natl Acad Sci U S A; 2005 Mar; 102(12):4560-5. PubMed ID: 15767578 [TBL] [Abstract][Full Text] [Related]